Skip to main content

Ionis to present at upcoming investor conferences

Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will participate in fireside chats at the following investor conferences:

  • 2025 Wells Fargo Healthcare Conference on Thursday, September 4, 2025
  • H.C. Wainwright 27th Annual Global Investment Conference on Monday, September 8, 2025
  • Morgan Stanley 23rd Annual Global Healthcare Conference on Tuesday, September 9, 2025

A live webcast of these presentations can be accessed on the Investors & Media section of the Ionis website at https://ir.ionis.com/events-and-presentations/upcoming-events. Replays will be available on the Ionis website within 48 hours and will be archived for a limited time.

About Ionis Pharmaceuticals

For three decades, Ionis has invented medicines that bring better futures to people with serious diseases. Ionis currently has marketed medicines and a leading pipeline in neurology, cardiology, and other areas of high patient need. As the pioneer in RNA-targeted medicines, Ionis continues to drive innovation in RNA therapies in addition to advancing new approaches in gene editing. A deep understanding of disease biology and industry-leading technology propels our work, coupled with a passion and urgency to deliver life-changing advances for patients. To learn more about Ionis, visit Ionis.com and follow us on X (Twitter), LinkedIn and Instagram.

Contacts

Ionis Pharmaceuticals Investor Contact:

D. Wade Walke, Ph.D. – ir@ionis.com760-603-2331

Ionis Pharmaceuticals Media Contact:

Hayley Soffer – media@ionis.com – 760-603-4679

Recent Quotes

View More
Symbol Price Change (%)
AMZN  248.78
+0.38 (0.15%)
AAPL  271.13
+1.70 (0.63%)
AMD  244.57
+0.59 (0.24%)
BAC  53.59
+0.16 (0.31%)
GOOG  289.44
-1.15 (-0.40%)
META  626.24
-5.52 (-0.87%)
MSFT  503.72
-2.28 (-0.45%)
NVDA  194.93
-4.12 (-2.07%)
ORCL  235.31
-5.52 (-2.29%)
TSLA  440.79
-4.44 (-1.00%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.